Subcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination cycles

What Was Tested

The paper reports a study of HMG (Human Menopausal Gonadotropin), published as a clinical trial.

This study was undertaken to determine the feasibility of administering human menopausal gonadotropin subcutaneously for controlled ovarian hyperstimulation with intrauterine insemination.

Who Took Part

PubMed indexes the participants as adults, women only.

Study patients (n = 25) undergoing controlled ovarian hyperstimulation with intrauterine insemination infertility treatment between June 1998 and March 1999 self-administered human menopausal gonadotropin subcutaneously for ovulation induction.

Cycles (n = 39) were analyzed for duration of human menopausal gonadotropin treatment, total number of ampules of human menopausal gonadotropin used, peak serum estradiol level, number of mature follicles (> or =15 mm), cycle fecundity, and acceptability of the subcutaneous route of human menopausal gonadotropin administration.

How the Study Was Run

This was a prospective nonrandomized matched-group comparison.

Age-matched historical control subjects who followed the same protocol except for the route of human menopausal gonadotropin administration, which was instead intramuscular, were used for comparison.

What Was Measured

The subject headings attached to it are Estradiol, Feasibility Studies, Fertility, Fertility Agents, Female, Insemination, Artificial, Homologous, Menotropins and Menstrual Cycle.

What This Means in Plain Language

This is a clinical trial of HMG (Human Menopausal Gonadotropin).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (American journal of obstetrics and gynecology), a journal based in United States.

More context: the HMG (Human Menopausal Gonadotropin) compound page, all human trials.